Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SS Innovations International (SSII) Gains from Sales and Divestitures (2023 - 2026)

SS Innovations International recorded quarterly Gains from Sales and Divestitures of $191555.0 in Q1 2026, down 63.67% quarter-over-quarter from $527325.0 in Q4 2025.

SS Innovations International's Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $191555.0 for Q1 2026.

  • In Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $191555.0; the TTM figure through Mar 2026 stood at $191555.0 (changed N/A YoY), while the FY2025 annual figure was $527325.0, down 25.29% from the prior year.
  • Gains from Sales and Divestitures came in at $191555.0 for Q1 2026 at SS Innovations International, down from $527325.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $718556.0 in Q4 2023 to a low of $179147.0 in Q1 2024.
  • A 4-year average of $464489.6 and a median of $527325.0 in 2025 frame the typical range for Gains from Sales and Divestitures.
  • Across the five-year window, Gains from Sales and Divestitures slipped 1.77% in 2024 and dropped 25.29% in 2025, its largest moves.
  • SS Innovations International's Gains from Sales and Divestitures stood at $718556.0 in 2023, then slipped by 1.77% to $705865.0 in 2024, then retreated by 25.29% to $527325.0 in 2025, then slumped by 63.67% to $191555.0 in 2026.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $191555.0, $527325.0, and $705865.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 SS Innovations International 770.31 Mn 746.70 Mn 5.33 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 191,555.00
Mar 31, 2026 191,555.00
Dec 31, 2025 527,325.00
Dec 31, 2025 527,325.00
Dec 31, 2024 705,865.00
Dec 31, 2024 705,865.00
Mar 31, 2024 179,147.00
Mar 31, 2024 179,147.00
Dec 31, 2023 718,556.00
Dec 31, 2023 718,556.00